TRANYLCYPROMINE SULFATE Drug Interactions
Also known as: PARNATE
TRANYLCYPROMINE SULFATE (brand name: PARNATE) is a MAOIs. 1 INDICATIONS AND USAGE PARNATE is indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. PARNATE is not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug…TRANYLCYPROMINE SULFATE has 3 documented drug interactions in our database, including 3 contraindicated, 0 major, 0 moderate, and 0 minor interactions.
3
Contraindicated
0
Major
0
Moderate
0
Minor
Co-administration of sertraline and tranylcypromine is absolutely contraindicated due to a high risk of developing serotonin syndrome, a potentially life-threatening condition characterized by mental status changes, autonomic instability, and neuromuscular abnormalities. This interaction can lead to severe and rapid onset symptoms.
Mechanism
Sertraline inhibits serotonin reuptake, increasing synaptic serotonin levels. Tranylcypromine, an irreversible MAO inhibitor, prevents the metabolic breakdown of serotonin. The combined effect leads to excessive accumulation of serotonin in the central nervous system.
Clinical Management
Concomitant use of sertraline and tranylcypromine is strictly prohibited. A washout period of at least 14 days is required when switching from tranylcypromine to sertraline, and at least 14 days when switching from sertraline to tranylcypromine, to allow for drug elimination and enzyme regeneration.
The combination of fluoxetine and tranylcypromine is contraindicated due to a high risk of serotonin syndrome, a potentially life-threatening condition characterized by mental status changes, autonomic instability, and neuromuscular abnormalities. This interaction can lead to severe and fatal outcomes.
Mechanism
Fluoxetine inhibits the reuptake of serotonin, increasing its concentration in the synaptic cleft. Tranylcypromine, an irreversible MAO inhibitor, prevents the enzymatic breakdown of serotonin. The combined effect leads to excessive serotonergic activity in the central nervous system.
Clinical Management
This combination is strictly contraindicated. A washout period of at least 5 weeks is required after discontinuing fluoxetine before initiating tranylcypromine. Conversely, at least 2 weeks should pass after discontinuing tranylcypromine before starting fluoxetine.
Co-administration of escitalopram and tranylcypromine is absolutely contraindicated due to a severe and potentially fatal risk of serotonin syndrome. Symptoms can include mental status changes, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms.
Mechanism
Escitalopram increases serotonin levels by inhibiting its reuptake, while tranylcypromine, a non-selective MAOI, prevents the metabolic breakdown of serotonin. The combined effect leads to excessive serotonergic activity in the central nervous system.
Clinical Management
This combination is strictly contraindicated. A washout period of at least 14 days is required when switching from tranylcypromine to escitalopram, and at least 5 weeks when switching from escitalopram to tranylcypromine. Patients must be educated on the risks and symptoms of serotonin syndrome.
For complete prescribing information:
View full TRANYLCYPROMINE SULFATE monograph →Already managing multiple medications?
Compare prices for all your prescriptions at 67,000+ pharmacies with one free RxGo search.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.